FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian Cancer
FDA批准摘要:Mirvetuximab Soravtansine-Gynx用于治疗FRα阳性、铂类耐药卵巢癌
期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-23-0991
Dilawari, Asma; Shah, Mirat; Ison, Gwynn; Gittleman, Haley; Fiero, Mallorie H; Shah, Ankit; Hamed, Salaheldin S; Qiu, Junshan; Yu, Jingyu; Manheng, Wimolnut; Ricks, Tiffany K; Pragani, Rajan; Arudchandran, Arulvathani; Patel, Paresma; Zaman, Shadia; Roy, Arpita; Kalavar, Shyam; Ghosh, Soma; Pierce, William F; Rahman, Nam Atiqur; Tang, Shenghui; Mixter, Bronwyn D; Kluetz, Paul G; Pazdur, Richard; Amiri-Kordestani, Laleh